Remote Teams Offer Chance to Improve Difficult-to-Treat PsA Remote Teams Offer Chance to Improve Difficult-to-Treat PsA
Multidisciplinary team meetings with dermatologists, rheumatologists, and other healthcare professionals can be helpful to direct the best care for patients with difficult-to-treat psoriatic arthritis.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - July 17, 2023 Category: Dermatology Tags: Rheumatology News Source Type: news
Insights into suicidal behavior among psoriatic arthritis patients: a systematic review and a genetic linkage disequilibrium analysis - Parperis K, Kyriakou A, Voskarides K, Koliou E, Evangelou M, Chatzittofis A.
OBJECTIVES: To systematically assess the magnitude of suicidal behavior among PsA patients and identify associated risk factors. Also identify common genes or coinherited single nucleotide polymorphisms (SNPs) implicated in suicidal behavior and PsA. ... (Source: SafetyLit)
Source: SafetyLit - July 12, 2023 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Aurobindo Pharma subsidiary enters pact with BioFactura for biosimilar ustekinumab
CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma said it has entered into an exclusive license agreement with the US-based BioFactura to commercialize BFI-751, a proposed biosimilar to Stelara (ustekinumab). Ustekinumab is used for treating Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 10, 2023 Category: Pharmaceuticals Source Type: news
SNMMI: New technology improves whole-body PET image quality
CHICAGO - An augmented PET scanning technique can enhance the resolution an...Read more on AuntMinnie.comRelated Reading:
FDG-PET/CT reveals sites of COVID-19 brain infection
Whole-body PET/CT cuts scan time in melanoma patients
NaF-PET shows bone formation in psoriatic arthritis patients
Whole-body PET/CT for a child: 5 minutes, no sedation
New PET/CT scanners may offer safer imaging in children (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 24, 2023 Category: Radiology Source Type: news
S3 Episode 5: New on the Market: Why Use Psoriatic Arthritis Biosimilars? S3 Episode 5: New on the Market: Why Use Psoriatic Arthritis Biosimilars?
Join Drs Stanley Cohen and Jonathan Kay as they discuss biosimilars in PsA, which will hit the US market this summer. They cover everything from working with your pharmacy to counseling patients.Medscape (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - June 22, 2023 Category: Orthopaedics Tags: Rheumatology InDiscussion Source Type: news
Which x-ray is best for carpal injuries?
Hand x-rays appear as useful as standard wrist x-rays for diagnosing carpa...Read more on AuntMinnie.comRelated Reading:
Botswana study questions accuracy of bone age estimates
NaF-PET shows bone formation in psoriatic arthritis patients
Radiologists can help identify signs of elder abuse on imaging
Stick to x-rays for estimating children's bone age, researcher say
AI model can help diagnose pediatric buckle fractures (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 2, 2023 Category: Radiology Source Type: news
TREMFYA ® (guselkumab) Provides Sustained Improvements Across All Minimal Disease Activity Domains for Adults Living with Active Psoriatic Arthritis in Phase 3b Trial
SPRING HOUSE, PENNSYLVANIA, May 31, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 3b COSMOS clinical trial showing that treatment with TREMFYA® (guselkumab) provided sustainable improvements in all minimal disease activity (MDA)a domains through week 48 in adults living with active psoriatic arthritis (PsA) who previously had an inadequate response to one to two tumor necrosis factor inhibitors (TNFi-IR).[1] In a separate post-hoc analysis of the Phase 3 DISCOVER-1 and DISCOVER-2b clinical trial findings, TREMFYA was shown to be associated with prompt and su...
Source: Johnson and Johnson - May 31, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Upadacitinib in Psoriatic Arthritis With Axial Involvement Upadacitinib in Psoriatic Arthritis With Axial Involvement
Is upadacitinib a safe and effective treatment option for psoriatic arthritis patients with axial involvement?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 24, 2023 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Brepocitinib Beneficial for Moderate-to-Severe Psoriatic Arthritis
THURSDAY, May 18, 2023 -- For patients with moderately to severely active psoriatic arthritis, the tyrosine kinase 2/Janus kinase 1 inhibitor brepocitinib is effective for reducing symptoms, according to a study published online May 17 in Arthritis... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 18, 2023 Category: Pharmaceuticals Source Type: news
What I ’ve Learned From My Patients About the Challenges of Psoriatic Arthritis
Find out what one rheumatologist has learned from her patients about psoriatic arthritis. (Source: WebMD Health)
Source: WebMD Health - May 17, 2023 Category: Consumer Health News Source Type: news
Spotlight: Trends I See in Psoriatic Arthritis Treatment
Psoriatic arthritis can be tricky to treat. Now, specialized treatments can zero in on specific factors in people that take out lots of the guesswork. (Source: WebMD Health)
Source: WebMD Health - May 17, 2023 Category: Consumer Health News Source Type: news
Axial SpA vs Axial PsA: Different Entities? Axial SpA vs Axial PsA: Different Entities?
Features of axial psoriatic arthritis and axial spondyloarthritis overlap, but whether they ' re different diseases or on the same spectrum is unclear.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 9, 2023 Category: Consumer Health News Tags: Rheumatology News Source Type: news
First Phase 3 TREMFYA ® (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction Results Among Patients with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, May 9, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new efficacy and safety data from the Phase 3 QUASAR Induction Study evaluating the investigational use of TREMFYA® (guselkumab) in adults with moderately to severely active ulcerative colitis (UC)a who had an inadequate response or intolerance to conventionalb and/or advanced therapies.1,c The data show statistically significant and clinically meaningful improvements across symptomatic and histo-endoscopic outcome measures.1 Safety data were also consistent with the known safety profile of TREMFYA in ...
Source: Johnson and Johnson - May 9, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
S3 Episode 3: Breakthroughs in Basic Research for Psoriatic Arthritis S3 Episode 3: Breakthroughs in Basic Research for Psoriatic Arthritis
Drs Stanley Cohen and Christopher Ritchlin discuss advances in basic research for psoriatic arthritis, including new research using a humanized mouse model, combination therapy trials, and more.Medscape (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - April 25, 2023 Category: Orthopaedics Tags: Rheumatology InDiscussion Source Type: news
Psoriatic Arthritis: Types, Causes, Symptoms & Treatments
MONDAY, April 24, 2023 -- Most people have heard of osteoarthritis and rheumatoid arthritis. But for some, psoriatic arthritis is the new kid on the block. Here ’s what you need to know about psoriatic arthritis, including symptoms, types and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 24, 2023 Category: General Medicine Source Type: news
